Novartis (VTX:NOVN) has been assigned a CHF 80 price objective by analysts at Barclays in a note issued to investors on Tuesday, February 20th. The brokerage presently has a “sell” rating on the stock. Barclays’ price objective indicates a potential upside of 2.77% from the stock’s current price.
A number of other research firms also recently commented on NOVN. Berenberg Bank set a CHF 91 price objective on shares of Novartis and gave the company a “neutral” rating in a report on Friday, January 26th. Deutsche Bank set a CHF 90 price target on shares of Novartis and gave the stock a “neutral” rating in a report on Thursday, January 25th. S&P Global set a CHF 91 price target on shares of Novartis and gave the stock a “neutral” rating in a report on Thursday, January 25th. Morgan Stanley set a CHF 92 target price on shares of Novartis and gave the company a “buy” rating in a report on Thursday, January 25th. Finally, Kepler Capital Markets set a CHF 87 target price on shares of Novartis and gave the company a “buy” rating in a report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of CHF 88.88.
Shares of Novartis (NOVN) traded up CHF 0.14 during trading on Tuesday, reaching CHF 77.84. 8,280,000 shares of the company were exchanged, compared to its average volume of 5,960,000. The stock has a market cap of $202,920.00 and a price-to-earnings ratio of 25.19. Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.